-
REAL-WORLD EVIDENCE GENERATION IN ITALY: A COMPARATIVE ANALYSIS BASED ON THE HMA-EMA CATALOGUE OF REAL-WORLD DATA STUDIES
Aug 11, 2026, 17:16 PM -
THE INCLUSION OF NON-MANDATORY CLINICAL OUTCOME ASSESSMENTS IN HEALTH TECHNOLOGY ASSESSMENT REVIEWS IN ENGLAND, FRANCE, AND GERMANY: IMPLICATIONS FOR BENEFIT RATINGS, PRICING, AND SALES
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ANALYSIS OF RAPID MULTIPLEX PCR PANEL FOR SEPSIS DIAGNOSIS IN ICU PATIENTS: VERTICALLY PRIVATE PLAN IN BRAZIL
Aug 11, 2026, 17:16 PM -
DEVELOPMENT OF THE DUTCH VALUE SET FOR THE PROMIS PREFERENCE SCORE (PROPR)
Aug 11, 2026, 17:16 PM -
DIVERSITY IN HEALTH TECHNOLOGY ASSESSMENT (HTA) PRACTICES ACROSS LATIN AMERICA: A CROSS-COUNTRY REVIEW OF DECISION FRAMEWORKS, EVIDENCE REQUIREMENTS AND ACCESS LINKAGES
Aug 11, 2026, 17:16 PM -
SAME GENERATION, DIFFERENT STATE: REGIONAL DISPARITIES IN SICK LEAVE ACROSS BABY BOOMERS, GEN-X, MILLENNIALS, AND GEN-Z IN GERMANY
Aug 11, 2026, 17:16 PM -
CHALLENGE OF ATMP REIMBURSEMENT AND PATIENT ACCESS IN A CHANGING UK LANDSCAPE
Aug 11, 2026, 17:16 PM -
FROM PATIENT EXPERIENCE TO HEALTH OUTCOMES: UNDERSTANDING THE PATHWAYS IN CANCER CARE
Aug 11, 2026, 17:16 PM -
MODELING THE IMPACT OF SCALE-UP OF LONG-ACTING INJECTABLE PRE-EXPOSURE PROPHYLAXIS (LAI PREP) FOR HIV PREVENTION INBRAZIL: A HIGH-IMPACT INVESTMENT IN HIV PREVENTION
Aug 11, 2026, 17:16 PM -
PULSE CHECK: COMPARISON OF REPORTED AI-ASSISTED METHODS IN ONCOLOGY AND CARDIOVASCULAR DISEASE PROSPERO-REGISTERED SLR PROTOCOLS
Aug 11, 2026, 17:16 PM -
ECONOMIC AND HUMANISTIC OUTCOMES OF DESIDUSTAT VERSUS ERYTHROPOIETIN IN DIALYSIS-DEPENDENT CKD PATIENTS: EVIDENCE FOR VALUE-BASED KIDNEY CARE
Aug 11, 2026, 17:16 PM -
ARE RARE DISEASE CLINICAL TRIALS READY FOR EU JOINT CLINICAL ASSESSMENT (JCA)?
Aug 11, 2026, 17:16 PM -
UNDERSTANDING UNMET NEED IN THE CONTEMPORARY TREATMENT LANDSCAPE IN A EUROPEAN GENERALIZED MYASTHENIA GRAVIS POPULATION FROM BOTH PHYSICIAN AND PATIENT PERSPECTIVES: A REAL-WORLD STUDY
Aug 11, 2026, 17:16 PM -
DOES PARTICIPATION IN THE UK CANCER DRUGS FUND RESOLVE UNCERTAINTY AND IMPROVE STRENGTH OF CLINICAL EVIDENCE DURING NICE TECHNOLOGY APPRAISALS
Aug 11, 2026, 17:16 PM -
EVALUATING THE EFFECTIVENESS OF A CORPORATE CARE PATHWAY FOR PATIENTS WITH MULTIMORBIDITY IN THE BASQUE HEALTH SERVICE: A REGRESSION DISCONTINUITY DESIGN APPROACH
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF IDIOPATHIC INFLAMMATORY MYOPATHIES IN THE UNITED STATES: A RETROSPECTIVE CLAIMS DATA STUDY
Aug 11, 2026, 17:16 PM -
FISCAL VALUE OF IMMUNISATION PROGRAMS: WORLDWIDE EVIDENCE SUPPORTING GOVERNMENT INVESTMENT DECISIONS
Aug 11, 2026, 17:16 PM -
ATTITUDES TOWARDS PATIENT-CENTERED RARE DISEASE CARE AMONG PHYSICIANS IN FIVE EUROPEAN COUNTRIES: A CROSS-SECTIONAL SURVEY
Aug 11, 2026, 17:16 PM -
A MULTI-CRITERIA DECISION ANALYSIS FRAMEWORK FOR INNOVATIVE MEDICINE LISTING IN ALGERIA: DEVELOPMENT AND ILLUSTRATIVE APPLICATION TO SEMAGLUTIDE
Aug 11, 2026, 17:16 PM -
FRAMING AI-ENABLED EVIDENCE FOR HTA: A PRACTICAL TAXONOMY BY EVIDENCE DOMAINS AND LEVELS OF AI INVOLVEMENT
Aug 11, 2026, 17:16 PM
